Please login to the form below

Not currently logged in
Email:
Password:

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace
AstraZeneca, Marc Dunoyer

AstraZeneca (AZ) has announced that Marc Dunoyer will take over from Simon Lowth as the company's chief financial officer.

The decision ends a near four-month search for a replacement after Lowth announced in July his intention to leave the company for a similar role at natural gas firm BG Group.

Dunoyer only joined AZ in June this year as executive VP, global portfolio and product strategy, to support the company's global restructuring programme. He was previously head of the rare diseases business at big pharma rivals GlaxoSmithKline (GSK).

AZ's CEO Pascal Soriot said he was “delighted” with the appointment of Dunoyer.

“Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership,” said Soriot.

Dunoyer will begin his new role on November 1, reporting directly to Soriot.

AZ said his replacement as as executive VP, global portfolio and product strategy will be announced separately.

1st November 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....